CTOs on the Move

Ra Medical

www.ramed.com

 
Advanced Excimer Laser-Based Vascular and Dermatological Therapies We are a medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. We believe our products enhance patients` quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. We currently manufacture and market two lines of products: DABRA Catheter and Laser is cleared by the U.S. FDA as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, including peripheral artery disease (PAD) and critical limb ischemia (CLI). Pharos Excimer Laser is FDA ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ramed.com
  • 2070 Las Palmas Drive
    Carlsbad, CA USA 92011
  • Phone: 760.804.1648

Executives

Name Title Contact Details

Similar Companies

Informatics Outsourcing

Informatics Outsourcing is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CLS Holdings USA,

Cannabis Life Sciences is both a cannabis producer and retailer offering a wide variety of products through its brands, Oasis and City Trees.

Hudson Valley Senior Residence

Hudson Valley Senior Residence is a Kingston, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Roselani Place

Roselani Place is a Kahului, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.